Trials / Completed
CompletedNCT05245708
Effects of Oxytocin on Reinforcement Learning and Interoception
The Modulatory Effects of Oxytocin on Reinforcement Learning and Interoceptive Processing
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- University of Electronic Science and Technology of China · Academic / Other
- Sex
- Male
- Age
- 18 Years – 28 Years
- Healthy volunteers
- Accepted
Summary
The main aim of the study is to investigate whether intranasal oxytocin has effects on reinforcement learning under dynamic environment and interoceptive processing based on behavioral and electroencephalogram (EEG) responses.
Detailed description
A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. (1) Participants first complete a probabilistic reward learning task 45 minutes after treatment with behavioral (response time and accuracy) and EEG data (ERP components such as FRN, ERN and P300) being collected during this task. (2) A resting-state recording and a heartbeat counting task are conducted following the learning task with ECG and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), the Cognitive Flexibility Inventory(CFI), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the tasks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intranasal oxytocin | Each subject will be assigned to intranasal administration of oxytocin (24 IU). |
| DRUG | intranasal placebo | Each subject will be assigned to intranasal placebo. |
Timeline
- Start date
- 2021-04-15
- Primary completion
- 2021-09-20
- Completion
- 2021-12-15
- First posted
- 2022-02-18
- Last updated
- 2024-01-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05245708. Inclusion in this directory is not an endorsement.